Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Florida Health Daily.
Press releases published on March 26, 2025
iTeos präsentiert präklinische Daten zu EOS-215 – dem potenziellen Best-in-Class-Antikörper gegen TREM2 und neuartigen PTPN1/2-Inhibitor – auf der Jahrestagung 2025 der American Association for Cancer Research
GlobeNewswire
·
March 26, 2025
WATERTOWN, Mass. und GOSSELIES, Belgien, March 26, 2025 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), ein biopharmazeutisches Unternehmen im Bereich der klinischen Forschung, das Pionierarbeit bei der Erforschung und Entwicklung einer neuen …
iTeos présentera les données précliniques d’EOS-215, un anticorps anti-TREM2 supposé meilleur de sa catégorie, et d’un nouvel inhibiteur de PTPN1/2 lors de l’édition 2025 du congrès annuel de l’American Association for Cancer Research
GlobeNewswire
·
March 26, 2025
WATERTOWN, Massachusetts et GOSSELIES, Belgique, 26 mars 2025 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq : ITOS), une société biopharmaceutique au stade clinique pionnière dans la découverte et le développement d’une nouvelle génération de …
OmegaX Health ($OmegaX) Expands to Binance Smart Chain – The Future of AI Healthcare on Blockchain
GlobeNewswire
·
March 26, 2025
ELLWANGEN, Germany, March 26, 2025 (GLOBE NEWSWIRE) -- OmegaX Health ($OmegaX), a groundbreaking AI-powered healthcare ecosystem, is set to redefine the future of medicine by combining artificial intelligence and blockchain technology. Following a highly …
US Hematologists Show Cautious Optimism as Data Reveal Early Adoption Trends for Hympavzi (Pfizer) and Alhemo (Novo Nordisk) in Hemophilia A and B, According to Spherix Global Insights
GlobeNewswire
·
March 26, 2025
EXTON, PA, March 26, 2025 (GLOBE NEWSWIRE) -- The hemophilia treatment landscape is rapidly evolving, with newly launched therapies and gene therapies joining factor replacement therapies, Hemlibra, and Altuvio to create new options. The latest …
Stryker announces intention to nominate Manny Maceda to board of directors
GlobeNewswire
·
March 26, 2025
Portage, Michigan, March 26, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that its board of directors has nominated Emmanuel “Manny” Maceda for election to the company’s board at the 2025 Annual Meeting of Shareholders, scheduled for May 8, 2025. …
FDA Recognizes Newly Revised AAMI Sterilization, Ethylene Oxide Guidance
GlobeNewswire
·
March 26, 2025
Arlington, VA, March 26, 2025 (GLOBE NEWSWIRE) -- AAMI is pleased to announce that the FDA has amended its database of Recognized Consensus Standards, adding multiple AAMI documents in the agency’s latest round of updates announced in March 2025. This …
Dietary Supplements Industry Poised for $258.75 Billion Growth by 2029
GlobeNewswire
·
March 26, 2025
Delray Beach, FL, March 26, 2025 (GLOBE NEWSWIRE) -- The global dietary supplements market is experiencing substantial growth, with an estimated valuation of USD 179.53 billion in 2024. Projections indicate a robust compound annual growth rate (CAGR) of 7. …
Best SARMs For Bulking, Cutting, Muscle Growth, Fat Loss Where to buy SARMs, Alternative Stack For Sale - CrazyBulk
GlobeNewswire
·
March 26, 2025
NEW YORK, March 26, 2025 (GLOBE NEWSWIRE) -- SARMs for Bulking If you want to build muscle faster than usual, SARMs for bulking can help. Using a SARMs stack (a combination of supplements) gives better results than using just one supplement. This guide …
Sonnet BioTherapeutics Successfully Completes First Safety Review of SON-1010 in Combination with Trabectedin in Certain Sarcomas
GlobeNewswire
·
March 26, 2025
SON-1010 is being studied as a combination therapy with trabectedin (Yondelis®), the first FDA-approved treatment for two types of advanced soft tissue sarcoma after failure of standard chemotherapy, due to the potential for immune mechanism synergies and …
New administrative data in Truveta Data and features in Truveta Studio help researchers accelerate regulatory grade research
GlobeNewswire
·
March 26, 2025
BELLEVUE, Wash., March 26, 2025 (GLOBE NEWSWIRE) -- Today, Truveta announced that Truveta Data has expanded to include new administrative data to enable more comprehensive analyses of healthcare outcomes and patient journeys. The company also announced two …
Dr. Lyudmila Sarder Receives Prestigious U.S. Congressional Award for Women’s History Month
GlobeNewswire
·
March 26, 2025
WASHINGTON, March 26, 2025 (GLOBE NEWSWIRE) -- Dr. Lyudmila Sarder, MD, a highly esteemed internal medicine resident physician, has been honored with United States Congressional Recognition for her outstanding contributions to healthcare across Central …
BioSig Technologies Confirms Full Compliance with Nasdaq Requirements for Continued Listing on The Nasdaq Capital Market
GlobeNewswire
·
March 26, 2025
Los Angeles, CA, March 26, 2025 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (BSGM) (“BioSig” or the “Company"), a medical technology company delivering unprecedented accuracy and precision to intra-cardiac signal visualization, is pleased to announce …
InspireMD to Present at Upcoming 24th Annual Needham Virtual Healthcare Conference
GlobeNewswire
·
March 26, 2025
MIAMI, March 26, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Prime carotid stent system for the treatment of carotid artery disease and prevention of stroke, today announced management will present at the 24th Annual …
Relmada Therapeutics to Report Fourth Quarter 2024 Financial Results on Thursday, March 27, 2025
GlobeNewswire
·
March 26, 2025
CORAL GABLES, Fla., March 26, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada”, or “the Company”), a clinical-stage biotechnology company committed to advancing innovative breakthrough therapies, today announced plans to host a …
Silo Pharma Achieves Key Milestone with First Dosing in IND-Enabling GLP Study for SPC-15 as a Groundbreaking PTSD Treatment
GlobeNewswire
·
March 26, 2025
Preclinical Data to Support Advancement Toward First-in-Human Clinical Trials SARASOTA, FL, March 26, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on novel …
Bluejay Therapeutics Announces First Patient Dosed in AZURE-1 Global Pivotal Clinical Trial Evaluating Brelovitug (BJT-778) as a Monotherapy Treatment for Chronic Hepatitis D
GlobeNewswire
·
March 26, 2025
REDWOOD CITY, Calif., March 26, 2025 (GLOBE NEWSWIRE) -- Bluejay Therapeutics, a clinical-stage biopharmaceutical company dedicated to developing potentially life-changing therapeutics for serious viral and liver diseases, today announced that the first …
Intelligent Bio Solutions Secures Key U.S. Patent, Strengthening IP Protection Ahead of Planned 2025 Market Entry
GlobeNewswire
·
March 26, 2025
Company’s 6th U.S. patent adds to comprehensive IP portfolio protecting its unique drug screening technology Patent protection strengthens Company’s competitive position as it prepares for planned entry into multi-billion dollar U.S. market in 2025 NEW …
Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on April 3
GlobeNewswire
·
March 26, 2025
Houston, TX, March 26, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”) is pleased to invite investors to a webinar on April 3, 2025, at 4:15 p.m. ET. The exclusive event, hosted by RedChip Companies, will …
Prime Biome Reviews Controversy Disclosure Report: Surprising Facts and Figures Revealed
GlobeNewswire
·
March 26, 2025
ST. PETERSBURG, Fla., March 26, 2025 (GLOBE NEWSWIRE) -- In today's fast-paced world, guts and skin health has become a crucial aspect of total wellbeing. Prime Biome Gummies have attracted a lot of attention in the rapidly changing fields of intestinal …
BriaCell to Present Clinical and Preclinical Data at the 2025 AACR Conference
GlobeNewswire
·
March 26, 2025
PHILADELPHIA and VANCOUVER, British Columbia, March 26, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to …